News

Archive

Press release -September 10, 2019

Virpax® Pharmaceuticals Announces the Appointment of Three Independent Directors

Virpax appointed three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders.

Read more...

Press release -August 13, 2019

Virpax® Pharmaceuticals Announces the Proposed Development of A Long Acting Naloxone and Naltrexone Liposomal Delivery To Reverse Opioid Related Respiratory Depression

Virpax Licenses Technology from Yissum Research Development Company of the Hebrew University of Jerusalem.

Read more...

Press release -August 6, 2019

Virpax® Pharmaceuticals to Present at the 2019 Military Health System Research Symposium

Virpax is presenting two posters in the MHSRS Pain Management for the Future Fight on Wednesday, August 21, 2019.

Read more...

Press release -June 11, 2019

Virpax® Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel

Michèle C. Linde has been appointed as the Company’s Executive Vice President, General Counsel and Corporate Secretary.

Read more...

Press release -June 3, 2019

Virpax® Pharmaceuticals Selected for Two Presentations at the 2019 Military Health System Research Symposium

Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL.

Read more...

Webcast - May 2, 2019

Listen to our Webcast From ThinkEquity

The Chairman and CEO of Virpax® Pharmaceuticals, Anthony P. Mack, presented at the ThinkEquity Conference on May 2nd. If you missed it, or want to re-listen, you can access the archived webcast here.

Listen now...

Press release - April 24, 2019

Virpax® Pharmaceuticals to Present at ThinkEquity Conference

Anthony P. Mack, Chairman and CEO of Virpax will be presenting at the ThinkEquity Conference at 12:30 p.m. ET on Thursday, May 2, 2019.

Read more...

Press release - April 16, 2019

Virpax  Licenses Molecular Envelope Technology Intranasal Formulation From Nanomerics Ltd.

Virpax Pharmaceuticals has partnered with Naomerics Ltd. to develop a non-opioid Molecular Envelope Technology (MET) intranasal formulation for the management of chronic pain.

Read more...

Press release - December 27, 2018

Virpax Announces Successful Pre-IND Meeting for LBL100

Virpax Pharmaceuticals completed a successful pre-IND Meeting with the US Food and Drug Administration.

Read more...

News article - December 3, 2018

Is Biopharma Still Committed To Its Role In Public Health?

This article from Life Science Leader magazine features the views of top executives, including  Virpax's CEO Anthony Mack, on how the life sciences industry business model meets public health obligations.

Read more on lifescienceleader.com

Press release - September 12, 2018

Virpax Reports Pre-IND Guidance From FDA for DSF100

Under FDA guidance, Virpax Pharmaceuticals plans to finalize IND and prepare for Phase 1 human study.

Read more...

News article - July 3, 2018

Virpax inks ‘patch-in-a-can’ deal for pain management

Virpax Pharmaceuticals has licensed MedPharm’s topical spray technology to develop a transdermal patch for non-opioid pain management products.

Read more on in-pharmatechnologist.com

Press release - June 21, 2018

MedPharm Licenses Its MedSpray® Technology to Virpax

MedPharm Licenses Its MedSpray® ‘Patch-in-a-Can’ Technology to Virpax Pharmaceuticals for Non-Opioid Pain Management Products.

Read more...

Press release - June 4, 2018

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Virpax Pharmaceuticals signs technology license agreement with LipoCure to develop pain management products using its liposome drug delivery products.

Read more...

Press release - May 29, 2018

Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd

Virpax Pharmaceuticals has licensed MedPharm's "Patch-in-a-Can" MedSpray® Technology to develop non-opioid pain management products.

Read more...

Latest news

Press release - February 5, 2020

Virpax® Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition

Abstracts featuring DSF100 and NES100 will be presented at this year's exhibition.

Read more...

Press release - January 14, 2020

Virpax® to Develop Its Molecular Envelope Technology (MET) Intranasal Enkephalin Formulation for the Management of PTSD

Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal peptide for the management of Post-Traumatic Stress Disorder (PTSD).

Read more...

Press release - October 22, 2019

Michèle C. Linde Promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary for Virpax® Pharmaceuticals

Michèle C. Linde has been promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary.

Read more...

Corporate headquarters

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Phone   484-875-3195

Email     info@virpaxpharma.com

© Virpax® Pharmaceuticals. All Rights Reserved.